Business, energy, technology, markets and global industry news from Business News Today

AbCellera Biologics Inc.

PharmaDeviceNews AbCellera Biologics Inc.
Editorial infographic highlighting AbCellera’s ABCL635 programme, featuring an antibody graphic, laboratory visuals and symptom-tracking charts, with key points on an 83% reduction in hot flashes, upcoming safety results, new symptom data and the open question of durability.
Pharma & Biotech

One ABCL635 injection cut hot flashes by 83%. Can AbCellera prove the benefit lasts?

AbCellera will reveal new ABCL635 safety and symptom data after reporting an 83% hot flash reduction. Can its antibody sustain the benefit?

Read More
AbCellera’s ABCL635 Phase 2 trial is testing whether a long-acting neurokinin 3 receptor antibody can reduce moderate-to-severe menopause hot flashes and support a less frequent dosing approach. Representative image.
Pharma & Biotech

Can one injection challenge daily hot-flash drugs? AbCellera’s ABCL635 faces its first real efficacy test

AbCellera will report Phase 2 ABCL635 data on Aug. 10, testing whether a long-acting NK3 antibody can reduce menopause hot flashes.

Read More
Pharma & Biotech

What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment

AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.

Read More